{"id":4741,"date":"2026-04-24T16:58:45","date_gmt":"2026-04-24T16:58:45","guid":{"rendered":"https:\/\/stock999.top\/?p=4741"},"modified":"2026-04-24T16:58:45","modified_gmt":"2026-04-24T16:58:45","slug":"morgan-stanley-adjusts-unh-stock-price-target-after-earnings","status":"publish","type":"post","link":"https:\/\/stock999.top\/?p=4741","title":{"rendered":"Morgan Stanley adjusts UNH stock price target after earnings"},"content":{"rendered":"<p><\/p>\n<p>It\u2019s funny how you barely think about healthcare companies until you actually need them. And what we would all want to see at such times is a simple, smooth checkup and the quiet efficiency.\u00a0<\/p>\n<p>Not long ago, though, Wall Street was worried about UnitedHealth (UNH), with rising costs and pressure on margins weighing on sentiment. Then came the first-quarter 2026 earnings report, shifting the narrative and prompting Morgan Stanley to raise its price target. To me, it feels less like a bold call and more like the market is catching up to a strength that never really left.<\/p>\n<p>UnitedHealth Group (UNH) didn&#8217;t just beat expectations on April 22, 2026. It beat them in the places that mattered most. Just exactly where investors were looking. Shares ended the day up 7%. That\u2019s one of the clearest single-session signals that a turnaround story is beginning to find its footing.<\/p>\n<p>&#8220;We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency, and connectivity,&#8221; said UNH CEO Stephen Hemsley.<\/p>\n<p>&#8220;The print represents a strong start to &#8217;26 and sets a positive tone for MCOs. We expect<br \/>momentum can continue as UNH continues to execute and build credibility. Reiterate Top Pick.&#8221; Morgan Stanley said.<\/p>\n<p>Morgan Stanley raises UNH stock target after strong earnings<\/p>\n<p>Morgan Stanley moved quickly after earnings, raising its price target on UnitedHealth Group (UNH) from $375\u00a0 to $395, while maintaining its \u201cOverweight\u201d rating and Top Pick status.<\/p>\n<p>The move followed a stronger-than-expected first-quarter performance that shifted investor sentiment.<\/p>\n<p>UnitedHealth Group&#8217;s Q126 earnings release results:First-quarter 2026 revenues of $111.7 billion, up from $109.6 billion in the year-ago quarter (up 2%)Earnings of $6.90 per share; adjusted earnings of $7.23 per shareMedical care ratio of 83.9%, down from 84.8% in Q1 2025\u00a0Cash flows from operations of $8.9 billion, or 1.4 times net incomeFull-year 2026 EPS guidance raised to $18.27 per share from $17.772027 EPS: $20.95 (from $20.45)<br \/>\nSource: UnitedHealth Group First Quarter 2026 Results<\/p>\n<p>Shares rose about 7% following the report, reflecting renewed confidence in the company\u2019s recovery story.<\/p>\n<p>The medical loss ratio improvement is the number that matters most to managed care investors, and UNH delivered it. Per Morgan Stanley&#8217;s note, the favorable ratio was aided in part by prior-year development and a softer flu season. Meaning the second quarter, with full claims data visibility, will provide a cleaner read on the underlying cost trend by product.<\/p>\n<p align=\"center\">Related: Morgan Stanley names UnitedHealth a &#8220;Top Pick&#8221;<\/p>\n<p>Optum Health was the other critical proof point. The division&#8217;s first-quarter EBIT handily beat expectations, according to Morgan Stanley, offering early evidence that operational investments made in the second half of 2025 are beginning to convert into measurable results.\u00a0<\/p>\n<p>Clinical reviews increased 50% in UNH&#8217;s West region, and skilled nursing admissions fell 35% year over year in the first month of the new care navigation approach, according to the MS\u2019s note.<\/p>\n<p>Morgan Stanley says UNH is clearly moving in the right direction<\/p>\n<p>Morgan Stanley sees this as a key differentiator. In its first-quarter update, the company outlined a clear strategy. To deploy AI across administrative and clinical operations with an expected 2:1 financial return, and many programs paying back within 12 to 18 months. According to MS, the near-term ROI stands out in healthcare, where tech investments often take years to show results.<\/p>\n<p>Several initiatives are already delivering impact. Avery, a generative AI chatbot for UnitedHealthcare members, is reducing administrative friction and improving user experience. Optum Real, an AI-driven claims platform, is cutting manual adjudication costs by 76%, according to MS note.\u00a0<\/p>\n<p align=\"center\">Related: Morgan Stanley adjusts RTX price target after earnings<\/p>\n<p>Ambient AI is helping physicians and nurses automate clinical documentation at scale, while AI-enabled self-service at Optum Rx has reduced call center volumes by 25%, MS\u2019s note confirms.<\/p>\n<p>All internal AI development is being funneled through Optum Insight, building a proprietary pipeline that UNH plans to commercialize externally. Morgan Stanley views this untapped AI potential as a meaningful upside not yet reflected in consensus estimates, with an investor day in the second half of 2026 seen as a possible catalyst.<\/p>\n<p>Morgan Stanley&#8217;s UNH target and 2027 earnings reveal something<\/p>\n<p>Morgan Stanley&#8217;s revised price target of $395, up from $375, is grounded in a sum-of-the-parts analysis that values each of UNH&#8217;s major business segments separately against comparable peer multiples, according to the firm&#8217;s note.<\/p>\n<p>                        Morgan Stanley raises its price target on UnitedHealth Group (UNH) from $375 to $395.<\/p>\n<p>                    Morgan Stanley revised UNH\u2019s earnings estimates as follows:2026 adjusted EPS estimate raised to $18.27 from $17.772027 adjusted EPS estimate raised to $20.95 from $20.45Price target of $395 implies 18.9 times the firm&#8217;s 2027 EPS estimate<\/p>\n<p>Even after the 7% single-session move, UNH shares were trading at just 13.7 times Morgan Stanley&#8217;s 2028 EPS estimate of $25.34. Well below the stock&#8217;s five-year and ten-year historical forward price-to-earnings averages of 15.8 times and 15.2 times, respectively, according to Morgan Stanley.<\/p>\n<p>The more aggressive scenario in Morgan Stanley&#8217;s illustrative 2027 earnings bridge points to potential upside of 22% to the bank&#8217;s own estimates and 27% to consensus, if management executes against its stated margin targets, yielding a broad illustrative 2027 EPS range of $21.10 to $25.63, per the firm. That range doesn&#8217;t incorporate incremental AI-driven savings that could materialize on top.<\/p>\n<p>More Health Care:<\/p>\n<p>If your Medicare plan was canceled, do this nowHealth care costs are the wild card in year-end tax planning22 million Americans hit by ACA health insurance cliff after vote fails<\/p>\n<p>Management also reiterated confidence in its long-term margin targets across key segments, according to Morgan Stanley&#8217;s note, including Optum Health margins of 6% to 8%, Medicare Advantage improvement toward the high end of the 2% to 4% target range in 2027, and modest Medicaid margin improvements beginning next year.<\/p>\n<p>For you who have been waiting for evidence that the UNH recovery is more than narrative, the first quarter of 2026 just provided it.<\/p>\n<p align=\"center\">Related: UNH stock just did something to the Dow Jones you rarely see<\/p>\n<p>#Morgan #Stanley #adjusts #UNH #stock #price #target #earnings<\/p>\n","protected":false},"excerpt":{"rendered":"<p>It\u2019s funny how you barely think about healthcare companies until you actually need them. And&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[9671,1308,394,100,395,91,336,9905],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/4741"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4741"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/4741\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}